Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Roche argued that its obesity medications would prove to have advantages over its rivals’ — and that the demand for weight ...

Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop ...

Rivus already announced in August that the trial hit its key endpoint, but today fleshed out that win with some figures.

Roche is planning to launch 13 medicines by the end of the decade and cut research costs for new drugs by a fifth, according to a strategy update on Monday.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics ...

Roche said it plans to focus on five key therapeutic areas as part of its new pharma strategy through 2030. The company will prioritize work in the areas of neurology, oncology and hematology, ...

Roche’s current pharmaceutical portfolio will deliver growth through at least 2027, the company said. Schinecker has already ...